Case studies stall in review for process reasons, not writing reasons. A number has no source, a quote has no sign-off, or nobody agreed who owns the decision. The habit that prevents all three is to tie every claim to a source before you write it, and to name the approvers before you start.
Ask a medtech or biotech marketing lead how many case studies their team started last year and how many were published. The gap is usually wide, and when you ask what happened to the missing ones, the answer is rarely "the draft was bad." It is some version of "it got stuck."
Where they actually stall
Five patterns account for most of the stuck drafts I have seen on both the agency side and inside regulated marketing teams.
A number with no source. The draft says turnaround fell 40 percent. Legal asks where 40 percent came from. Nobody can find it. The sentence gets cut, and once the headline result is gone the story collapses around it.
A quote the customer does not recognise. A writer polished what the clinician said into something cleaner. The clinician will not sign it. Everyone goes quiet, because nobody wants to send the awkward follow-up.
Nobody agreed who decides. Marketing assumes regulatory will review. Regulatory assumes legal will. The draft sits in two inboxes for six weeks while each waits for the other.
The customer was asked too late. The story was written before permission existed. Permission arrives with conditions, usually "don't name us," which means the named draft is now the wrong draft.
A stakeholder joins late. Someone senior sees round two and wants a different angle. Round four begins, and the team that started the project has moved on.
The habit
Every one of those is prevented by the same discipline, applied before the first sentence is written: tie every claim to a source, and name the owners.
In practice that means a ledger. One row per claim: the exact wording as it will appear, the document or transcript it came from, the person responsible for checking it, and its status. When the draft arrives with that table, a regulatory reviewer verifies instead of investigating, which is the difference between a two-day review and a six-week one.
And it means a short list of owners, agreed up front: who owns the angle, who confirms clinical or scientific statements, who approves quotes on the customer side, who gives the final go. One name per row. If "final approval" is a committee, the story waits for the slowest member.
What to do this week
If you have a stuck draft right now, do two things. Build the ledger for it, even retroactively; you will find the unsupported claims in twenty minutes. Then send one email that names the owners and asks for one consolidated round of comments by a date. Most stuck drafts move within days once those two things exist.
If you are starting a new one, the approval workflow guide lays out the owners and the order, and the free source ledger template is the table described above.
Want this produced for you?
Upload your materials and get a fully sourced first draft within two business days of a complete intake. No interviews, no sales call.
Written Case Study from $1,495. Complete Case Study Kit $3,495. Pay online, then complete the intake. No calls.